Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Replicate Bioscience Announces Positive Results for Next-Generation srRNA Technology
Details : RBI-4000 is a novel self-replicating RNA (srRNA) vaccine candidate, which stimulate virus-neutralizing immune responses to rabies. It is being developed for the treatment of rabies infection.
Product Name : RBI-4000
Product Type : Vaccine
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
Details : RBI-4000, is an next generation srRNA technology vaccine developed to stimulate virus-neutralizing immune responses to rabies virus for prophylactic use.
Product Name : RBI-4000
Product Type : Vaccine
Upfront Cash : Inapplicable
December 09, 2023
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Curia
Deal Size : Inapplicable
Deal Type : Inapplicable
Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
Details : RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.
Product Name : RBI-4000
Product Type : Vaccine
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : RBI-4000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Curia
Deal Size : Inapplicable
Deal Type : Inapplicable